查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844349

自体免疫疾病诊断市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球自体免疫疾病诊断市场价值为 57 亿美元，预计将以 6.6% 的复合年增长率成长，到 2034 年达到 110 亿美元。

自体免疫疾病诊断市场 - IMG1

自体免疫疾病发生率的上升、早期诊断意识的增强、筛检计画的持续推​​进以及诊断技术的稳步进步，正在推动市场扩张。医疗保健支出的增加和创新早期检测工具的引入也增强了对精准快速检测的需求。从分子检测到免疫测定和基于生物标记的检测，诊断能力正在不断发展，以满足日益增长的临床需求。由政府和医疗机构主导的患者教育活动正在显着提高检测量。同时，利用特定生物标记的精准诊断技术正得到更广泛的应用，透过早期疾病检测和针对患者的监测来改善治疗效果。便携式快速自体免疫疾病检测解决方案也越来越受欢迎，能够在各种护理环境中提供更快的结果，进一步推动市场发展。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 57亿美元
预测值 110亿美元
复合年增长率 6.6%

2024年，试剂和耗材细分市场占据67%的市场份额，这得益于其在自体免疫检测程序中的重复使用。诊断应用对检测试剂盒、抗体和缓衝液的持续需求推动了该细分市场的持续成长。随着诊断和长期疾病监测的检测越来越频繁，对这些材料的需求也持续成长。实验室和诊所严重依赖耗材进行准确且有效率的诊断，从而为该细分市场创造了稳定的收入来源。

局部自体免疫疾病领域在2024年创造了40亿美元的市场规模，预计到2034年将以6.4%的复合年增长率成长。该领域包括甲状腺疾病、发炎性肠道疾病和第1型糖尿病等针对特定器官的疾病，这些疾病在全球的诊断率日益上升。这些器官特异性疾病的增多，推动了对局部疾病检测的高敏感度和精准诊断的需求。为了避免长期併发症，早期介入和持续监测的需求推动了该领域的持续成长。

2024年，北美自体免疫疾病诊断市场占36.6%的市场。该地区是全球自体免疫疾病发生率最高的地区之一，包括多发性硬化症、红斑性狼疮、类风湿性关节炎和第1型糖尿病。不断增长的患者群体推动了对高级诊断检测的巨大需求。凭藉强大的医疗基础设施和广泛的筛检计划，该地区持续支持常规和高级自体免疫检测。对早期诊断和个人化护理的重视进一步维持了市场的成长。

全球自体免疫疾病诊断市场的主要活跃参与者包括欧陆、赛默飞世尔科技、罗氏、Quest Diagnostics、Inova Diagnostics (Werfen)、DIAsource、Trinity Biotech、Revvity、Labcorp、西门子医疗、GRIFOLS、Hemagen Diagnostics、BIO-UX、RADBIOMERIE 和雅培。自体免疫疾病诊断市场的公司正在透过策略合作、收购和对先进技术的投资来扩大其产品组合。许多公司专注于开发基于生物标记的诊断方法和下一代分子工具，以提高灵敏度和速度。研发投入的增加使公司能够推出更精确、更用户友好的诊断平台，包括即时检测试剂盒。公司还优先考虑自动化，以简化实验室工作流程并提高通量。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 自体免疫疾病发生率高、盛行率高
      • 对自体免疫疾病的认识不断提高
      • 政府对自体免疫疾病研究活动的支持政策
      • 技术进步和实验室自动化技术的日益普及
    • 产业陷阱与挑战
      • 进阶诊断测试成本高昂
      • 测试结果的周转时间较长，需要进行多次诊断测试
    • 市场机会
      • 人工智慧和机器学习在诊断领域的应用日益广泛
      • 家庭和自我诊断试剂盒的成长
  • 成长潜力分析
  • 监管格局
    • 北美洲
    • 欧洲
    • 亚太地区
  • 技术格局
    • 当前的技术趋势
    • 新兴技术
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 未来市场趋势

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲和中东
  • 竞争定位矩阵
  • 主要市场参与者的竞争分析
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

  • 主要趋势
  • 试剂和耗材
  • 仪器

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

  • 主要趋势
  • 局限性自体免疫疾病
    • 1型糖尿病
    • 发炎性肠道疾病
    • 甲状腺
    • 其他局部自体免疫疾病
  • 系统性自体免疫疾病
    • 类风湿关节炎
    • 系统性红斑狼疮（SLE）
    • 多发性硬化症
    • 牛皮癣
    • 其他系统性自体免疫疾病

第七章：市场估计与预测：按测试类型，2021 - 2034

  • 主要趋势
  • 抗核抗体检测
  • 自体抗体检测
  • 全血球计数（CBC）
  • C反应蛋白（CRP）
  • 尿液分析
  • 其他测试类型

第八章：市场估计与预测：依最终用途，2021 - 2034 年

  • 主要趋势
  • 医院
  • 诊断中心
  • 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • Abbott
  • BIOMERIEUX
  • BIO-RAD
  • DIAsource
  • Euroimmun
  • GRIFOLS
  • Hemagen Diagnostics
  • Inova Diagnostics (Werfen)
  • Labcorp
  • Quest Diagnostics
  • Revvity
  • Roche
  • SIEMENS Healthineers
  • Thermo Fisher Scientific
  • Trinity Biotech
简介目录
Product Code: 618

The Global Autoimmune Disease Diagnostics Market was valued at USD 5.7 billion in 2024 and is estimated to grow at a CAGR of 6.6% to reach USD 11 billion by 2034.

Autoimmune Disease Diagnostics Market - IMG1

Rising incidence rates of autoimmune conditions, higher awareness about early diagnosis, ongoing screening programs, and steady advancements in diagnostic technologies are fueling market expansion. Improved healthcare spending and the introduction of innovative tools for early detection have also strengthened the demand for accurate and rapid testing. From molecular assays to immunoassays and biomarker-based detection, diagnostic capabilities are evolving to meet growing clinical needs. Patient education campaigns, led by both governments and healthcare organizations, are significantly raising testing volumes. At the same time, precision diagnostics utilizing specific biomarkers are seeing greater adoption, improving outcomes through early disease detection and patient-specific monitoring. Portable and rapid testing solutions for autoimmune disorders are also gaining popularity, offering quicker results in various care settings and further driving market momentum.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$5.7 Billion
Forecast Value$11 Billion
CAGR6.6%

In 2024, the reagents and consumables segment held 67% share owing to their recurring use in autoimmune testing procedures. The constant need for assay kits, antibodies, and buffers across diagnostic applications is contributing to the segment's consistent growth. As testing becomes more frequent for both diagnosis and long-term disease monitoring, the demand for these materials continues to rise. Laboratories and clinics rely heavily on consumables to perform accurate and efficient diagnostics, creating a steady revenue stream within the segment.

The localized autoimmune disease segment generated USD 4 billion in 2024 and is expected to grow at a CAGR of 6.4% through 2034. This segment includes conditions such as thyroid disorders, inflammatory bowel diseases, and Type 1 diabetes diseases targeting specific organs and increasingly being diagnosed worldwide. The rise in these organ-specific conditions fuels the need for highly sensitive and precise diagnostics tailored to localized disease detection. Continued growth in this area is supported by the need for early intervention and consistent monitoring to avoid long-term complications.

North America Autoimmune Disease Diagnostics Market held 36.6% share in 2024. The region reports one of the highest rates of autoimmune disorders globally, including multiple sclerosis, lupus, rheumatoid arthritis, and Type 1 diabetes. This growing patient population drives significant demand for advanced diagnostic testing. With a strong healthcare infrastructure and widespread screening initiatives, the region continues to support both routine and advanced autoimmune testing. The emphasis on early diagnosis and personalized care further sustains market growth.

Major players active in the Global Autoimmune Disease Diagnostics Market include Euroimmun, Thermo Fisher Scientific, Roche, Quest Diagnostics, Inova Diagnostics (Werfen), DIAsource, Trinity Biotech, Revvity, Labcorp, Siemens Healthineers, GRIFOLS, Hemagen Diagnostics, BIO-RAD, BIOMERIEUX, and Abbott. Companies in the autoimmune disease diagnostics market are expanding their portfolios through strategic collaborations, acquisitions, and investments in advanced technologies. Many are focusing on developing biomarker-based diagnostics and next-generation molecular tools to improve sensitivity and speed. Increased investment in R&D is enabling firms to introduce more precise and user-friendly diagnostic platforms, including point-of-care testing kits. Companies are also prioritizing automation to streamline lab workflows and enhance throughput.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Disease Type trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 High incidence and prevalence of autoimmune diseases
      • 3.2.1.2 Growing awareness about autoimmune diseases
      • 3.2.1.3 Supportive government policies for research activities on autoimmune diseases
      • 3.2.1.4 Technological advancements and increasing adoption of lab automation technologies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced diagnostic tests
      • 3.2.2.2 Slow turnaround time for test results and need for multiple diagnostic tests
    • 3.2.3 Market opportunities
      • 3.2.3.1 Increasing adoption of AI and machine learning in diagnostics
      • 3.2.3.2 Growth in home-based and self-diagnostic kits
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
    • 4.3.5 LAMEA
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Reagents and consumables
  • 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Localized autoimmune disease
    • 6.2.1 Type 1 diabetes
    • 6.2.2 Inflammatory bowel disease
    • 6.2.3 Thyroid
    • 6.2.4 Other localized autoimmune diseases
  • 6.3 Systemic autoimmune disease
    • 6.3.1 Rheumatoid arthritis
    • 6.3.2 Systemic lupus erythematosus (SLE)
    • 6.3.3 Multiple sclerosis
    • 6.3.4 Psoriasis
    • 6.3.5 Other systemic autoimmune diseases

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Antinuclear antibody tests
  • 7.3 Autoantibody tests
  • 7.4 Complete blood count (CBC)
  • 7.5 C-reactive protein (CRP)
  • 7.6 Urinalysis
  • 7.7 Other test types

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostics centers
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott
  • 10.2 BIOMERIEUX
  • 10.3 BIO-RAD
  • 10.4 DIAsource
  • 10.5 Euroimmun
  • 10.6 GRIFOLS
  • 10.7 Hemagen Diagnostics
  • 10.8 Inova Diagnostics (Werfen)
  • 10.9 Labcorp
  • 10.10 Quest Diagnostics
  • 10.11 Revvity
  • 10.12 Roche
  • 10.13 SIEMENS Healthineers
  • 10.14 Thermo Fisher Scientific
  • 10.15 Trinity Biotech